On May 7, according to the website of the State Food and Drug Administration, in accordance with the relevant provisions of the "Regulations on the Administration of Narcotic Drugs and Psychotropic Substances", the State Drug Administration, the Ministry of Public Security, and the National Health Commission decided to adjust the list of psychotropic drugs, and the announcement is as follows:
1. Dextromethorphan, diphenoxylate-containing combination preparations, nalfuraphine and lorcaserin are included in the list of Class II psychotropic drugs.
2. The midazolam API and injection will be adjusted from Class II psychotropic drugs to Class I psychotropic drugs, and other unilateral preparations of midazolam will remain Class II psychotropic drugs.
This announcement will come into force on July 1, 2024.
According to the data, dextromethorphan is a central antitussive drug, and this product is a dextrol isomer of morphine levomorphan methyl ether, which exerts a central antitussive effect by inhibiting the medullary cough center.
In December 2021, the State Food and Drug Administration issued an announcement to convert the unilateral formulation of dextromethorphan hydrobromide into a prescription drug.
On December 1, 2022, the "List of Prohibited Drugs for Online Sales (First Edition)" was officially implemented, and dextromethorphan has been banned from online sales since then.
In the two batches of typical cases of online drug sales announced by the State Food and Drug Administration in 2023, some merchants were punished for selling dextromethorphan online.
(Source: Jiupai News Comprehensive State Drug Administration)